IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
IDEAYA Biosciences (NASDAQ: IDYA) has announced its participation in two upcoming investor relations events in April 2025. The company will participate in:
- The 2025 RBCCM Ophthalmology Conference on April 3rd, 2025 at 11:30 AM ET, featuring a fireside chat with CEO Yujiro S. Hata and CMO Darrin Beaupre
- The Stifel 2025 Virtual Targeted Oncology Forum on April 8th, 2025 at 12:00 PM ET, featuring CEO Yujiro S. Hata
Live audio webcasts will be available on the company's investor relations website, with replays accessible for 30 days after the events.
IDEAYA Biosciences (NASDAQ: IDYA) ha annunciato la sua partecipazione a due eventi di relazioni con gli investitori in aprile 2025. L'azienda parteciperà a:
- La Conferenza di Oftalmologia RBCCM 2025 il 3 aprile 2025 alle 11:30 AM ET, con un incontro informale con il CEO Yujiro S. Hata e il CMO Darrin Beaupre
- Il Forum Virtuale di Oncologia Targeted Stifel 2025 l'8 aprile 2025 alle 12:00 PM ET, con il CEO Yujiro S. Hata
Le webcasts audio in diretta saranno disponibili sul sito web delle relazioni con gli investitori dell'azienda, con le registrazioni accessibili per 30 giorni dopo gli eventi.
IDEAYA Biosciences (NASDAQ: IDYA) ha anunciado su participación en dos próximos eventos de relaciones con inversores en abril de 2025. La empresa participará en:
- La Conferencia de Oftalmología RBCCM 2025 el 3 de abril de 2025 a las 11:30 AM ET, con un chat informal con el CEO Yujiro S. Hata y el CMO Darrin Beaupre
- El Foro Virtual de Oncología Dirigida Stifel 2025 el 8 de abril de 2025 a las 12:00 PM ET, con el CEO Yujiro S. Hata
Las transmisiones web de audio en vivo estarán disponibles en el sitio web de relaciones con inversores de la empresa, con repeticiones accesibles durante 30 días después de los eventos.
IDEAYA 바이오사이언스 (NASDAQ: IDYA)는 2025년 4월에 열리는 두 개의 투자자 관계 행사에 참여할 것이라고 발표했습니다. 회사는 다음 행사에 참여합니다:
- 2025년 4월 3일 오전 11:30 ET에 열리는 2025 RBCCM 안과학 컨퍼런스, CEO 유지로 S. 하타와 CMO 다린 보프레와의 대화가 포함됩니다.
- 2025년 4월 8일 오후 12:00 ET에 열리는 스티펠 2025 가상 표적 종양학 포럼, CEO 유지로 S. 하타가 참여합니다.
실시간 오디오 웹캐스트는 회사의 투자자 관계 웹사이트에서 제공되며, 이벤트 후 30일 동안 다시 볼 수 있습니다.
IDEAYA Biosciences (NASDAQ: IDYA) a annoncé sa participation à deux événements de relations avec les investisseurs prévus en avril 2025. L'entreprise participera à :
- La Conférence d'Ophthalmologie RBCCM 2025 le 3 avril 2025 à 11h30 ET, avec une discussion informelle avec le PDG Yujiro S. Hata et le directeur médical Darrin Beaupre
- Le Forum Virtuel d'Oncologie Ciblée Stifel 2025 le 8 avril 2025 à 12h00 ET, avec le PDG Yujiro S. Hata
Des webcasts audio en direct seront disponibles sur le site web des relations avec les investisseurs de l'entreprise, avec des rediffusions accessibles pendant 30 jours après les événements.
IDEAYA Biosciences (NASDAQ: IDYA) hat seine Teilnahme an zwei bevorstehenden Investor Relations-Veranstaltungen im April 2025 angekündigt. Das Unternehmen wird teilnehmen an:
- Der 2025 RBCCM Augenheilkunde-Konferenz am 3. April 2025 um 11:30 Uhr ET, mit einem informellen Gespräch mit CEO Yujiro S. Hata und CMO Darrin Beaupre
- Dem Stifel 2025 Virtuellen Zielgerichteten Onkologie-Forum am 8. April 2025 um 12:00 Uhr ET, mit CEO Yujiro S. Hata
Live-Audio-Webcasts werden auf der Investor Relations-Website des Unternehmens verfügbar sein, mit Aufzeichnungen, die 30 Tage nach den Veranstaltungen zugänglich sind.
- None.
- None.
2025 RBCCM Ophthalmology Conference
Thursday, April 3rd, 2025 at 11:30 AM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer and Darrin Beaupre, Chief Medical Officer, hosted by Gregory Renza, M.D., Director and Senior Biotechnology Research Analyst
Stifel 2025 Virtual Targeted Oncology Forum
Tuesday, April 8th, 2025 at 12:00 PM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by hosted by Benjamin Burnett, Ph.D., Managing Director, Equity Analyst
A live audio webcast of the conference events, as permitted by the conference host, will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcast will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Chief Accounting Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-participation-in-upcoming-april-2025-investor-relations-events-302416278.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
When is IDEAYA Biosciences (IDYA) presenting at the RBCCM Ophthalmology Conference 2025?
Who will represent IDEAYA Biosciences (IDYA) at the Stifel Virtual Targeted Oncology Forum?
Where can investors access IDEAYA Biosciences (IDYA) conference webcasts?
What investor conferences is IDEAYA Biosciences (IDYA) attending in April 2025?
